NEW YORK, Sept. 15 /PRNewswire/ -- Often fatal “orphan diseases,” which affect relatively few people -- under 200,000 -- seldom get as much attraction as heart disease, for example. A small pharmaceutical company is trying to change that.
NEW YORK, Sept. 15 /PRNewswire/ -- Often fatal “orphan diseases,” which affect relatively few people -- under 200,000 -- seldom get as much attraction as heart disease, for example. A small pharmaceutical company is trying to change that.
